Tag Archives: NASDAQ:CLSD

Clearside Biomedical Received its Third Buy in a Row

After J.P. Morgan and Wedbush assigned a Buy rating to Clearside Biomedical in the last month, the company received another Buy, this time from Cowen & Co.. Analyst Boris Peaker reiterated a Buy rating on Clearside Biomedical (NASDAQ: CLSD) yesterday.

Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (NASDAQ: CLSD) and Agile Therapeutics (NASDAQ: AGRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clearside Biomedical (NASDAQ: CLSD) and Agile Therapeutics (NASDAQ: AGRX) with bullish sentiments. Clearside Biomedical (NASDAQ: CLSD) Wedbush analyst Liana Moussatos reiterated a

Cowen & Co. Releases a Buy Rating on Clearside Biomedical

In a report released today, Boris Peaker from Cowen & Co. reiterated a Buy rating on Clearside Biomedical (NASDAQ: CLSD). The company’s shares opened today at $7.42. Peaker said: “This morning CLSD announced accrual completion of its Phase 1/2 DME

Cowen & Co. Thinks Clearside Biomedical’s Stock is Going to Recover

In a report released today, Boris Peaker from Cowen & Co. reiterated a Buy rating on Clearside Biomedical (NASDAQ: CLSD). The company’s shares opened today at $6.96, close to its 52-week low of $5.44. According to TipRanks.com, Peaker is a

Wedbush Thinks Clearside Biomedical’s Stock is Going to Recover

In a report released yesterday, Liana Moussatos from Wedbush maintained a Buy rating on Clearside Biomedical (NASDAQ: CLSD), with a price target of $28. The company’s shares closed yesterday at $7.64, close to its 52-week low of $5.65. According to